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Abstract: B a c k g r o u n d: The purpose of this study was to describe clinical manifestations, labo-
ratory findings and outcome of granulomatosis with polyangiitis (GPA) in pediatric patients living in 
two regions (Southern and Central) of Poland.
M e t h o d s: Retrospective analysis of patient hospital records from four large hospitals during 
a period from 1995 to 2013. Patients with confirmed diagnosis of GPA according to American College 
of Rheumatology (ACR) and EULAR/PRINTO/PRES criteria for GPA were analyzed. All patients were 
subjected to clinical, laboratory, radiological and immunological assessment.
R e s u l t s: During this 18-year period only 9 children with confirmed diagnosis of GPA (6 girls, 
3 boys) were identified. The average age of the disease onset was 12 years (range: 8–16 years). Average 
delay between first symptoms and diagnosis was approx. 20 months (range: 0–84 months). Organ 
system involvement at presentation included: kidneys 88.8% (8/9), lungs 77.7% (7/9), ear/nose/
throat 55.5% (5/9), gastrointestinal tract 55.5% (5/9), skin 44.4% (4/9), joints 22.2% (2/9), eyes 
11.1% (1/9) and nervous system 11.1% (1/9). In 5 children disease course was progressive (constant 
progression of sinusitis in one case, end-stage renal disease in two, chronic kidney disease stage IV 
in one and one child died due to alveolar hemorrhage).
C o n c l u s i o n: The majority of our patients were females. Clinical features of pediatric GPA were 
similar to those described in adults. None of our patients developed subglottic stenosis and in only 
2 children saddle-nose deformity was observed. Although GPA was treated according to contemporary 
standards care, disease progression was observed in more than a half of children. 
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INTRODUCTION
Granulomatosis with polyangiitis (GPA; formerly Wegener’s granulomatosis) is 
a systemic, necrotizing vasculitis affecting small and medium-sized blood vessels, 
associated with granulomatous inflammation [1, 2]. Clinically, this disease mani-
fests itself mainly through constitutional symptoms together with the involvement 
of respiratory tract and kidneys [3]. The disease was first described in 1936 by 
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a German pathologist — Friedrich Wegener [4]. Nowadays it was proposed to 
abandon eponyms and use the name of granulomatosis with polyangiitis [4]. 
Reported annual incidence of GPA varies between 0.5 and 10 cases per one 
million [5–7]. This disease usually manifests itself in the 6th and 7th decade of 
life, with similar frequency between genders in adult age [5]. Its occurrence in 
childhood has also been reported [2, 8–11], with one case diagnosed as early as 
in the second week of life [12]. The incidence of pediatric GPA is not well estab-
lished with boys to girls ratio from 1:1 to 1:4 [9]. Disease course in adulthood 
and childhood can differ [1]. It was suggested that GPA in childhood is more 
frequently complicated by a subglottic stenosis and nasal deformity [13]. On the 
other hand, treatment related morbidity and disease progression might be less 
common in children [13]. GPA in both children and adults is fatal if left untreat-
ed. Induction treatment and chronic therapy is crucial for going into remission 
and maintaining relapse-free disease. Early medical data, obtained before imple-
mentation of effective treatment showed mean survival of about 5 months, with 
more than 90% of patients dying within the first 2 years after diagnosis [7]. The 
aim of our study was to provide data on pediatric GPA in four major hospitals 
from Central and Southern Poland [12] and to compare this experience with the 
limited (mainly case reports) literature.
PATIENTS AND METHODS
We retrospectively analyzed paper medical records of children hospitalized in 
two large pediatric hospitals (Polish-American Children’s Hospital and St. Louis 
Children Hospital, both in Cracow), one department of internal medicine compri-
sing systemic vasculitis reference center (2nd Department of Internal Medicine, 
Jagiellonian University Medical College) also in Cracow (administrative region of 
Southern Poland — 3.3 million inhabitants) and one pediatric reference center 
in a central region of the country (Nephrology Division, Department of Paediatrics 
and Immunology Polish Mother Memorial Hospital Research Institute in Łódź). We 
systematically collected organ specific clinical, laboratory and imaging features 
at presentation, and at any time, and measures of outcome, such as remission, 
progression and refractory disease. Analyzed records came from the period of 
1995–2013. Patients were entered into the study, if they had at least 2 out of 
the 4 criteria according to the ACR or at least 3 out of the 6 criteria according to 
the EULAR/PRINTO/PRES [11, 14]. However, there are no precise and unequivocal 
diagnostic criteria and it’s important to base the diagnosis on clinical symptoms 
(such as epistaxis, haemoptysis with cough and dyspnoe, haematuria, general 
edema, skin lesions), histopathological picture of affected organ (s) and the pre-
sence of anti-neutrophil cytoplasmic antibodies (ANCA) [6, 10–12]. In follow-up 
these signs can also be observed as indicators of GPA relapse. 
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RESULTS
In all four hospitals, during the period of 18 years, diagnosis of GPA was esta-
blished in only nine children (6 girls and 3 boys). The average age of disease onset 
was 12 years (range: 8–16 years). The average delay between first symptoms and 
diagnosis was approx. 20 months (range: 0–84 months) (Table 1). At presenta-
tion the most common symptoms were constitutional ones: weight loss, fever or 
arthralgia. They were presented in all children except for one. Organ involvement 
at presentation included: kidneys 88.8% (8/9), lungs 77.7% (7/9), ear/nose/si-
nuses/throat 55.5% (5/9), gastrointestinal tract 55.5% (5/9), skin 44.4% (4/9), 
joints 22.2% (2/9), eyes 11.1% (1/9) and nervous system 11.1% (1/8) (Table 2). 
Later, in the course of the disease, upper and lower airway and kidney involve-
ment prevailed (Table 2). Anti-neutrophil cytoplasmic antibodies (ANCA) were po-
sitive in all patients. Their presence, however, is not absolutely necessary for a 
clinical diagnosis of GPA. Other common laboratory abnormalities at diagnosis 
included: proteinuria 100% (9/9), hematuria 88.8% (8/9) and abnormal chest 
X-ray 77.7% (7/9) or chest CT scan 77.7% (7/9). Six children reported chronic 
rhinitis, but sinusitis in CT or X-ray was confirmed in only four. Our analysis 
included 18 years of medical history. During this time recommendations for GPA 
treatment have been constantly changing. Moreover, new immunosuppression re-
gimens were invented. For this reason, and due to delayed diagnosis, each child 
was treated in a different way. All patients received glucocorticosteroids (GCS) 
Number Gender Age at diagnosis Age of onset Diagnosis delay (years)
Patient 1 W 11 11 0
Patient 2 W 20 13 7
Patient 3 W 13 12 1
Patient 4 M 15 15 0
Patient 5 W 11 11 0
Patient 6 M 10 8 2
Patient 7 W 13 9 4
Patient 8 W 16 16 0
Patient 9 M 14 13 1
Average     13.66 12     1.66
T a b l e  1
Demographic data, delay in diagnosis, treatment at diagnosis of GPA and disease activity score  
at presentation.
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T a b l e  2
Clinical manifestation at diagnosis GPA and at any time after diagnosis of GPA.
At presentation At any time
Constitutional symptoms 8 9
 Fever 5 7
 Arthralgias 3 3
 Weight loss 5 6
Renal involvement 8 8
 Glomerulonephritis 8 8
 Requirement for dialysis 2 3
 Kidney tranplatation 0 1
Ear, nose,  
throat involvement
5 8
 Rhinitis 4 6
 Sinusitis 4 4
 Epistaxis 2 2
 Oral ulcers 2 2
 Otitis media 1 3
 Nasal ulcers 0 0
 
Conductive/sensorineural 
deafness 1 1
 Saddle nose 0 2
 Subglottic stenosis 0 0
 Nasal septal perforation 0 4
Pulmonary involvement 7 8
 Alveolar hemorrhage 3 4
 Nodules 3 4
 Fixed infiltrates 2 2
 Required ventilation 0 1
 Pleuritis 2 2
Eye involvement 1 1
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At presentation At any time
 Conjunctivitis 1 1
 Scleritis/episcleritis 0 0
 Proptosis 0 0
Skin involvement 4 4
 Petechiae/palpable purpura 4 4
 Urticaria 1 1
 
Panniculitis/erythematous 
nodules 1 1
Arthritis 2 3
Hypertension 1 2
Gastrointestinal involvement 5 5
 Abdominal pain 5 5
 Gastrointestinal bleeding 2 3
Venous thrombotic event
 1 1
 Deep vein thrombosis 1 1
 Pulmonary embolus 0 0
Nervous system involvement 1 2
and cyclophosphamide (CTX). In addition, mycophenolate mofetil was used in 
four children and cyclosporine in one. In four children plasmapheresis was used 
and two children required chronic hemodialysis. In five patients disease course 
was progressive in spite of treatment with cyclophosphamide and corticosteroids 
(constant progression of sinusitis in one case, end-stage renal disease in two, 
chronic kidney disease stage IV in one, one child died due to alveolar hemorrhage). 
The child, who died was the youngest of our patients at the time of the first GPA 
symptoms (8 years of age with 2 years delay in diagnosis). In all five children 
progression was observed after steroid withdrawal. Progression of sinusitis was 
mainly a consequence of delayed diagnosis and a very low maintenance dose of 
corticosteroid (on average 0.1 mg per kg every other day). In one child progres-
sion (renal failure) developed on mycophenolate mofetil combined with low-dose 
steroids. Three (out of four) children who achieved stable and long lasting disease 
remission were diagnosed and treated without delay. Their remission induction 
treatment included oral prednisone (0.5 mg/per kg/per day), or periodic infusion 
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of intravenous high-doses of methyloprednisolone, and intravenous cyclophospha-
mide. In our group of patients, apart from increased risk of infections, no other 
important clinical side effects of immunosuppressive therapy were observed. 
DISCUSSION
Based on our material we are not able to precisely specify the prevalence of pe-
diatric GPA in Poland. Our estimation, however, indicates approximate frequency 
of about 0.05 per 100 000 children per year in analysed region, which is proba-
bly less than the real. In the available literature GPA incidence among children 
is also not well established, but estimated between 0.03 and 3.2 per 100 000 
children per year, with boys to girls ratio from 1:1 to 1:4 [9, 7, 12, 15]. Recen-
tly, the number of newly diagnosed cases of GPA constantly increases. This is 
possibly due to increased awareness of its existence [6, 7, 9]. The median of age 
at first symptoms in our study was 12 years (range: 8–16 years); higher than 
that reported by Belostotsky et al. (6 years) [12], but lower than those published 
by Stegmayr et al. (17.8 years) [16], Akikusa et al. (14.5 years) [2] and Cabral 
et al. (13.975 years) [11]. The adult literature and pediatric study performed by 
Stegmayr et al. suggested an equal male/female ratio or male predominance [16]. 
However, in our study, similarly to those performed by Belostotsky et al. [16], 
Cabral et al. [11] and Akikusa et al. [2] predominance of girls was evident. Cli-
nical manifestations of pediatric GPA is usually different than that observed in 
adults and this is probably the most important reason for delayed diagno-
sis [1]. In our group of patients the diagnosis was also significantly delayed 
(by 20 months on average) even though 7 of 9 children at presentation had co-
existence of symptoms from upper and/or lower airways and kidneys. This relates 
to poor awareness of this disease in children among family doctors and pedia-
tricians in the Polish health system, probably because of its rarity in children. 
Other reasons may include variable course, sometimes limited to constitutional 
symptoms only [17], which may lead to wrong diagnosis and mistreatment of GPA 
in children. As an example — two of our patients were initially diagnosed with 
Schoenlein-Henoch purpura. This caused a substantial delay in the institution 
of a proper immunosuppressive therapy and in effect in severe and irreversible 
organ damage (kidney failure and destruction of parasinusal bones, respectively). 
Constitutional symptoms in children GPA are always presented at the time of 
diagnosis, accompanied by rhinitis (87%) and kidney involvement (86%) [2, 17]. 
Frequency of rhinitis and sinusitis may continue to grow during the further 
course of the disease [2, 12]. Based on the data from 23 GPA children Rottem 
et al. reported that this form of disease is five times more often complicated by 
subglottic stenosis and two times more often by nasal deformity. Belostotsky et al. 
made a similar observation in their group of 17 children with GPA [12]. In con-
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trast, none of our patients developed subglottic stenosis and only in two children 
saddle-nose deformity was observed. A reason for rare occurrence of above-men-
tioned symptoms lies probably in a higher age at first symptoms. Ophthalmologic 
complications and peripheral neuropathy was presented in 11% and 22% of our 
patients, respectively. This roughly corresponds to the available literature [13].
In summary, even though GPA affects mainly adult patients, pediatricians 
must be aware of this possibility. Diagnosis should be made as quickly as possi-
ble to avoid irreversible organ damage or even death. Especially, when there are 
symptoms from upper and/or lower respiratory tract and kidneys, GPA should 
be always considered. We can describe these signs as a diagnostic “red flag”.
ABBREVIATIONS AND ACRONYMS
ACR  — American College of Rheumatology 
ANCA  — anti-neutrophil cytoplasmic antibodies 
EULAR/PRINTO/PRES — European League Against Rheumatism/Paediatric Rheumatology Interna- 
   tional Trials Organisation/Paediatric Rheumatology European Society 
CTX  — cyclophosphamide 
GCS  — glucocorticosteroids 
GPA  — granulomatosis with polyangiitis 
MMF  — mycophenolate mofetil 
WG   — Wegener’s granulomatosis
REFERENCES
1. Pełkowska A., Sancewicz-Pach K., Słowiaczek E., et al.: Diagnostic difficulties in 15-year-old boy 
with Wegener granulomatosis. Przegl Pediatr. 2005; 35: 174–177. — 2. Akikusa J.D., Schneider R., Har-
vey E.A., et al.: Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis Rheum. 
2007; 57: 837–844. — 3. Wong S.N., Shah V., Dillon M.J.: Antineutrophil cytoplasmic antibodies in 
Wegener’s granulomatosis. Arch Dis Child. 1998; 79: 246–250. — 4. Kucharz E.J., Majdan M., Kotuls- 
ka A.: Ziarniniakowatość z zapaleniem naczyń — nowa nazwa ziarniniakowatości Wegenera i potrzeba 
jej upowszechnienia. Reumatologia. 2012; 50: 541–542. — 5. Morales-Angulo C., García-Zornoza R., Obe-
so-Agüera S., et al.: Ear, nose and throat manifestations of Wegener’s granulomatosis (granulomatosis 
with polyangiitis). Acta Otorrinolaringol Esp. 2012; 63: 206–211. — 6. Rodrigues C.E., Callado M.R., No-
bre C.A., et al.: Wegener’s granulomatosis: prevalence of the initial clinical manifestations—report of 
six cases and review of the literature. Rev Bras Reumatol. 2010; 50: 150–164. — 7. Takwoingi Y.M., 
Dempster J.H.: Wegener’s granulomatosis: an analysis of 33 patients seen over a 10-year period. 
Clin Otolaryngol Allied Sci. 2003; 28: 187–194. — 8. Ziakas N.G., Boboridis K., Gratsonidis A., 
et al.: Wegener’s granulomatosis of the orbit in a 5-year-old child. Eye (Lond). 2004; 18: 658–660. 
— 9. Ludwichowska A., Cieszyńska J., Piotrowski S., et al.: Otological manifestations of Wege-
ner’s granulomatosis in 14-year boy — case study. Forum Medycyny Rodzinnej. 2012; 6: 175–181. 
— 10. Siomou E., Tramma D., Bowen C., et al.: ANCA-associated glomerulonephritis/systemic 
vasculitis in childhood: clinical features-outcome. Pediatr Nephrol. 2012; 27: 1911–1920.
11. Cabral D.A., Uribe A.G., Benseler S., et al.: Classification, presentation, and ini-
tial treatment of Wegener’s granulomatosis in childhood. Arthritis Rheum. 2009; 60: 3413–
12
3424. — 12. Belostotsky V.M., Shah V., Dillon M.J.: Clinical features in 17 paediatric patients 
with Wegener granulomatosis. Pediatr Nephrol. 2002; 17: 754–761. — 13. Frosch M., Foell D.: 
Wegener granulomatosis in childhood and adolescence. Eur J Pediatr. 2004; 163: 425–434. 
— 14. Ozen S., Pistorio A., Iusan S.M., et al.: EULAR/PRINTO/PRES criteria for Henoch-Schön-
lein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood 
Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010; 69: 798–
806. — 15. Smolewska E., Biernacka-Zielińska M., Szadkowska A., et al.: Wegener’s granulomatosis in 
a 14-year-old boy — a multidisciplinary approach. Przegl Pediatr. 2005; 35: 234–240. — 16. Steg- 
mayr B.G., Gothefors L., Malmer B., et al.: Wegener granulomatosis in children and young 
adults. A case study of ten patients. Pediatr Nephrol. 2000; 14: 208–213. — 17. Jóźwiakowska M., 
Tuszkiewicz-Misztal E., Górnicka G.: Wegener granulomatosis — case report. Przegl Pediatr. 2005; 
35: 234–240. 
1 2nd Department of Internal Medicine 
Unit of Allergy and Clinical Immunology 
Jagiellonian University, Medical College  
Kraków, Poland
2 University Hospital 
Unit of Allergy and Clinical Immunology  
Kraków, Poland
3 University Children’s Hospital 
Unit of Nephrology and Hypertension  
Kraków, Poland
4 University Children’s Hospital 
Unit of Pulmonology, Allergy and Dermatology  
Kraków, Poland
5 Polish Mother Memorial Hospital Research Institute 
Nephrology Division,  
Department of Paediatrics and Immunology  
Łódź, Poland
6 St. Luis Children’s Hospital 
Unit of Older Children with Subunit of Neurology,  
Rheumatology and Rehabilitation 
Kraków, Poland  
Corresponding author:
Joanna Kosałka MD 
2nd Department of Internal Medicine 
Unit of Allergy and Clinical Immunology 
Jagiellonian University Medical College 
ul. Skawińska 8, 31-066 Kraków, Poland 
Phone: +48 669 233 755  
Fax: +48 12 430 52 03 
E-mail: joanna.kosalka@gmail.com
